I-Mab (NASDAQ: IMAB), a Nasdaq-listed company since 2020, announced that the first patient has been dosed in a global multi-center Phase I clinical study for its TJ-CD4B (ABL111), a bispecific antibody (BsAb) targeting Claudin 18.2 (CLDN18.2) and 4-1BB, in solid tumors including gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma, and pancreatic ductal adenocarcinoma.
Drug Profile
TJ-CD4B is designed to bind to tumor lesions even in cases of low CLDN18.2 expression, a capability that distinguishes it from similar therapies. This feature positions the drug as a potential treatment for cancers with low CLDN18.2 expression. The drug received orphan drug designation (ODD) for gastric cancer in the US in March 2023.
Clinical Trial
The Phase I study is being conducted in China and the US concurrently, focusing on multiple solid tumors. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of TJ-CD4B in patients with gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma, and pancreatic ductal adenocarcinoma.
Collaboration
TJ-CD4B is being co-developed by South Korean firm ABL Bio in markets outside Greater China under a deal signed in 2018.-Fineline Info & Tech
